FindTrial
Sign In

Ad26.Mos4.HIV

BIOLOGICAL7 trials

Sponsors

Janssen Vaccines & Prevention B.V., Boris Juelg, MD PhD, Henry M. Jackson Foundation for the Advancement of Military Medicine

Conditions

Acquired Immunodeficiency SyndromeHIVHIV-1HIV-1-infectionHealthyHuman Immunodeficiency VirusImmunologic Deficiency Syndrome, AcquiredRetroviridae Infections

Phase 1

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults
CompletedNCT02788045
Janssen Vaccines & Prevention B.V.Healthy
Start: 2016-07-08End: 2022-04-25Updated: 2025-05-25
A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults
CompletedNCT02935686
Janssen Vaccines & Prevention B.V.Healthy
Start: 2017-03-31End: 2023-11-22Updated: 2025-05-25
A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment
CompletedNCT03307915
Janssen Vaccines & Prevention B.V.Human Immunodeficiency Virus
Start: 2018-03-05End: 2021-11-05Updated: 2025-02-04
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
Active, not recruitingNCT04983030
Boris Juelg, MD PhDAcquired Immunodeficiency Syndrome, HIV, Immunologic Deficiency Syndrome, Acquired +2
Start: 2022-04-01End: 2026-04-30Target: 36Updated: 2026-01-12
Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission
WithdrawnNCT05769569
Henry M. Jackson Foundation for the Advancement of Military MedicineHIV-1-infection
Start: 2023-09-01End: 2025-07-01Updated: 2024-05-03

Phase 2

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa
TerminatedNCT03060629
Janssen Vaccines & Prevention B.V.HIV-1
Start: 2017-11-03End: 2022-02-02Updated: 2023-04-18

Phase 3

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
CompletedNCT03964415
Janssen Vaccines & Prevention B.V.Healthy
Start: 2019-10-31End: 2023-08-10Updated: 2024-07-31

Related Papers

Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.
2025-12-01
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost
PLOS Global Public Health2025-04-11
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Emerging Microbes & Infections2025-04-071 citations
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection
JCI Insight2025-02-235 citations
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
2024-07-1924 citations
The Question of HIV Vaccine: Why Is a Solution Not Yet Available?
Journal of Immunology Research2024-01-0112 citations
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults
Journal of Clinical Investigation2023-02-1412 citations
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
The Journal of Infectious Diseases2022-11-0733 citations
Components of a HIV-1 vaccine mediate virus-like particle (VLP)-formation and display of envelope proteins exposing broadly neutralizing epitopes.
2022-01-2211 citations
Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.
2021-06-1127 citations
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
2020-10-0175 citations
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
2018-07-06276 citations